Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myeloid, Acute 17Multiple Myeloma 15Myelodysplastic Syndromes 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 6Hodgkin Disease 5Hematologic Neoplasms 5Myeloproliferative Disorders 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Anemia, Refractory, with Excess of Blasts 4Recurrence 3Neuroblastoma 3Neoplasm, Residual 3Leukemia, Myelomonocytic, Juvenile 3Graft vs Host Disease 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Precancerous Conditions 2Neoplasms, Plasma Cell 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Leukemia 2Immunoblastic Lymphadenopathy 2

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Venentoclax × Melphalan × 90 days × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡